Discharge of patients with metastatic castration-resistant prostate cancer after therapy with 177Lu-PSMA-617

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038833

Enrollment

Registered

2026-03-06

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Single-arm retrospective observational study: Patients with metastatic castration-resistant prostate cancer from January 2025 to December 2025 who received 177Lu-PSMA therapy and imaging afte

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed mCRPC, dosage: 5920–8140 MBq Pluvicto® every 5–10 weeks, renal function: eGFR = 45 mL/min.

Exclusion criteria

Exclusion criteria: Contradiction to the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Tumor uptake and dose rate 48 hours after administration of 177Lu-PSMA.	—

Secondary

Measure	Time frame
1. eGFR value and dose rate 48 hours after administration of 177Lu-PSMA. 2. 6th cycle of therapy or discontinuation of therapy after the 2nd cycle of therapy.	—

Countries

Germany

Contacts

Public ContactSergey Danilov

Vivantes - Netzwerk für Gesundheit GmbH, Institut für Nuklearmedizin

sergey.danilov@vivantes.de+4930130142085

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026